Inhibitor Therapeutics (INTI) Cash & Equivalents (2012 - 2026)

Inhibitor Therapeutics (INTI) has 15 years of Cash & Equivalents data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 70.13% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 70.13% YoY) and the FY2025 annual result came in at $2.4 million, down 57.63% from the prior year.
• Cash & Equivalents fell to $1.3 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $12.0 million in Q4 2022 to a low of $24945.0 in Q2 2022.
• A 5-year average of $5.5 million and a median of $5.6 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 75.06% — and 2023, when it soared 40390.39%.
• Tracing INTI's Cash & Equivalents over 5 years: stood at $12.0 million in 2022, then declined by 26.03% to $8.8 million in 2023, then slumped by 36.57% to $5.6 million in 2024, then tumbled by 57.63% to $2.4 million in 2025, then tumbled by 45.65% to $1.3 million in 2026.
• The last three Cash & Equivalents figures came in at $1.3 million (Q1 2026), $2.4 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.